hypertrophic cardiomyopathy

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

News

BMS lines up follow-up indication for cardiomyopathy drug Ca...

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the compan

News

BMS bags FDA okay for cardiomyopathy drug mavacamten

Bristol-Myers Squibb's has become the first company to bring a cardiac myosin inhibitor through to FDA approval, claiming a green light from the US regulator for mavacamten as a therapy for

News

BMS builds case for mavacamten label ahead of FDA decision

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for th

News

Look out BMS, Cytokinetics has its eye on mavacamten's turf

Shares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) that could tread on the toes of Bristol-Myers Squibb's ma

Cytokinetics rockets on positive heart drug trial

BMS lines up follow-up indication for cardiomyopathy drug Ca...

BMS bags FDA okay for cardiomyopathy drug mavacamten

BMS builds case for mavacamten label ahead of FDA decision

Look out BMS, Cytokinetics has its eye on mavacamten's turf

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

hypertrophic cardiomyopathy

Editor's Picks